We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-21.81%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$222M
AUM Growth
-$100M
Cap. Flow
-$21.8M
Cap. Flow %
-9.81%
Top 10 Hldgs %
58.76%
Holding
56
New
11
Increased
13
Reduced
17
Closed
9

Top Buys

Rank Stock Value
1
TELA icon
TELA Bio
TELA
+$9.68M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.68M
3
CUTR
Cutera, Inc.
CUTR
+$7.8M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.98M
5
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
+$1.88M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$14.4M
2
BCYC
Bicycle Therapeutics
BCYC
+$7.68M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.66M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$5.96M
5
CYTK icon
Cytokinetics
CYTK
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
51
Protagonist Therapeutics
PTGX
$9.67B
– –
-251,500
Closed -$5.96M
RPTX
52
DELISTED
Repare Therapeutics
RPTX
– –
-55,678
Closed -$793K
SMLR
53
DELISTED
Semler Scientific
SMLR
– –
-70,000
Closed -$3.47M
STRO icon
54
Sutro Biopharma
STRO
$353M
– –
-8,998
Closed -$740K
SYBX
55
DELISTED
Synlogic
SYBX
– –
-65,613
Closed -$2.36M
AVEO
56
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-240,000
Closed -$1.34M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2022 Portfolio in Review

As of Q2 2022, Opaleye Management held 56 positions worth $222M, down 31% from $322M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management withdrew a net $21.8M in Q2 2022, closing 9 positions and reducing 17 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $7.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Inhibrx, Inc. Common Stock worth $6.7M.

  • Opaleye Management's largest Q2 2022 buy was Inhibrx, Inc. Common Stock: 590,000 shares worth $6.7M.
  • Opaleye Management added most to TELA Bio in Q2 2022, an estimated $9.68M increase.
  • Opaleye Management's biggest Q2 2022 reduction was Chimerix, Inc., cutting an estimated $14.4M.
  • Opaleye Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $7.68M.
  • Opaleye Management's ten largest holdings make up 59% of its $222M portfolio in Q2 2022.
  • Opaleye Management opened 11 new positions and closed 9 in Q2 2022.
  • Opaleye Management's portfolio value fell 31% quarter-over-quarter to $222M.

Based on Opaleye Management's 13F filing for Q2 2022, filed 15 Aug 2022.